| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H10N6.C4H6O6 |
| Molecular Weight | 340.292 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1
InChI
InChIKey=HLSKIRWZKAEOEB-LREBCSMRSA-N
InChI=1S/C8H10N6.C4H6O6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;5-1(3(7)8)2(6)4(9)10/h1-4H,9-10H2,(H,11,13)(H,12,14);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
Approval Year
PubMed
Patents
Sample Use Guides
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration:
Intravenous
ACTIVE MOIETY
SUBSTANCE RECORD
